<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35650294</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Plasma taurine is an axonal excitability-translatable biomarker for amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>9155</StartPage><MedlinePgn>9155</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9155</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-13397-6</ELocationID><Abstract><AbstractText>Although various body fluid biomarkers for amyotrophic lateral sclerosis (ALS) have been reported, no biomarkers specifically reflecting abnormalities in axonal excitability indices have currently been established. Capillary electrophoresis time-of-flight mass spectrometry and liquid chromatography time-of-flight mass spectrometry were used to perform a comprehensive metabolome analysis of plasma from seven ALS patients and 20 controls, and correlation analysis with disease phenotypes was then performed in 22 other ALS patients. Additionally, electrophysiological studies of motor nerve axonal excitability were performed in all ALS patients. In the ALS and control groups, levels of various metabolites directly associated with skeletal muscle metabolism, such as those involved in fatty acid &#x3b2;-oxidation and the creatine pathway, were detected. Receiver operating characteristic curve analysis of the top four metabolites (ribose-5-phosphate, N6-acetyllysine, dyphylline, 3-methoxytyrosine) showed high diagnostic accuracy (area under the curve&#x2009;=&#x2009;0.971) in the ALS group compared with the control group. Furthermore, hierarchical cluster analysis revealed that taurine levels were correlated with the strength-duration time constant, an axonal excitability indicator established to predict survival. No significant effects of diabetes mellitus and treatment (Riluzole and Edaravone) on this relationship were detected in the study. Therefore, plasma taurine is a potential novel axonal excitability-translatable biomarker for ALS.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakazato</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanai</LastName><ForeName>Kazuaki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fukushima Medical University, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataura</LastName><ForeName>Tetsushi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nojiri</LastName><ForeName>Shuko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Research Center, Juntendo University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hattori</LastName><ForeName>Nobutaka</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saiki</LastName><ForeName>Shinji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. ssaiki@juntendo.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>1EQV5MLY3D</RegistryNumber><NameOfSubstance UI="D013654">Taurine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013654" MajorTopicYN="N">Taurine</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests<b>.</b></CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35650294</ArticleId><ArticleId IdType="pmc">PMC9160240</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-13397-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-13397-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron, D El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin. Neurophysiol. 2008;119:497&#x2013;503. doi: 10.1016/j.clinph.2007.09.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al. Prognostic factors in ALS: A critical review. Amyotroph. Lateral Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Swash M. Fasciculation potentials: A study of amyotrophic lateral sclerosis and other neurogenic disorders. Muscle Nerve. 1998;21:336&#x2013;344. doi: 10.1002/(SICI)1097-4598(199803)21:3&lt;336::AID-MUS7&gt;3.0.CO;2-B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4598(199803)21:3&lt;336::AID-MUS7&gt;3.0.CO;2-B</ArticleId><ArticleId IdType="pubmed">9486862</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265&#x2013;267. doi: 10.1212/01.wnl.0000194316.91908.8a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimura-Kiyono C, et al. Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2011;82:1244&#x2013;1249. doi: 10.1136/jnnp-2011-300141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-300141</ArticleId><ArticleId IdType="pubmed">21921087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai K, et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2012;83:734&#x2013;738. doi: 10.1136/jnnp-2011-301782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-301782</ArticleId><ArticleId IdType="pubmed">22566594</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang QJ, et al. Promoting identification of amyotrophic lateral sclerosis based on label-free plasma spectroscopy. Ann. Clin. Transl. Neurol. 2020;7:2010&#x2013;2018. doi: 10.1002/acn3.51194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51194</ArticleId><ArticleId IdType="pmc">PMC7545607</ArticleId><ArticleId IdType="pubmed">32951348</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimaki M, et al. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology. 2018;90:e404&#x2013;e411. doi: 10.1212/WNL.0000000000004888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004888</ArticleId><ArticleId IdType="pmc">PMC5791797</ArticleId><ArticleId IdType="pubmed">29298852</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis. Lancet Neurol. 2016;15:673&#x2013;684. doi: 10.1016/S1474-4422(16)00070-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00070-3</ArticleId><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Saiki S, et al. Decreased long-chain acylcarnitines from insufficient beta-oxidation as potential early diagnostic markers for Parkinson's disease. Sci. Rep. 2017;7:7328. doi: 10.1038/s41598-017-06767-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-06767-y</ArticleId><ArticleId IdType="pmc">PMC5544708</ArticleId><ArticleId IdType="pubmed">28779141</ArticleId></ArticleIdList></Reference><Reference><Citation>Saiki S, et al. A metabolic profile of polyamines in parkinson disease: A promising biomarker. Ann. Neurol. 2019;86:251&#x2013;263. doi: 10.1002/ana.25516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25516</ArticleId><ArticleId IdType="pmc">PMC6772170</ArticleId><ArticleId IdType="pubmed">31155745</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeshige-Amano H, et al. Shared metabolic profile of caffeine in parkinsonian disorders. Mov. Disord. 2020;35:1438&#x2013;1447. doi: 10.1002/mds.28068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28068</ArticleId><ArticleId IdType="pmc">PMC7496239</ArticleId><ArticleId IdType="pubmed">32357260</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, et al. Metabolomics in amyotrophic lateral sclerosis: how far can it take us? Eur. J. Neurol. 2016;23:447&#x2013;454. doi: 10.1111/ene.12956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12956</ArticleId><ArticleId IdType="pubmed">26822316</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefera TW, Borges K. Metabolic dysfunctions in amyotrophic lateral sclerosis pathogenesis and potential metabolic treatments. Front. Neurosci. 2016;10:611. doi: 10.3389/fnins.2016.00611.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2016.00611</ArticleId><ArticleId IdType="pmc">PMC5222822</ArticleId><ArticleId IdType="pubmed">28119559</ArticleId></ArticleIdList></Reference><Reference><Citation>Bereman MS, et al. Metabolite profiling reveals predictive biomarkers and the absence of beta-methyl amino-l-alanine in plasma from individuals diagnosed with amyotrophic lateral sclerosis. J. Proteome Res. 2020;19:3276&#x2013;3285. doi: 10.1021/acs.jproteome.0c00216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.0c00216</ArticleId><ArticleId IdType="pmc">PMC8273918</ArticleId><ArticleId IdType="pubmed">32418425</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson DL, Cox MM, Lehninger AL. Lehninger Principles of Biochemistry. 7. W.H. Freeman and Company; 2017. pp. 667&#x2013;693.</Citation></Reference><Reference><Citation>Lanznaster D, et al. Plasma creatinine and amyotrophic lateral sclerosis prognosis: A systematic review and meta-analysis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2019;20:199&#x2013;206. doi: 10.1080/21678421.2019.1572192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1572192</ArticleId><ArticleId IdType="pubmed">30961401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, et al. Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2020;21:263&#x2013;272. doi: 10.1080/21678421.2020.1746810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1746810</ArticleId><ArticleId IdType="pmc">PMC7373369</ArticleId><ArticleId IdType="pubmed">32276554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropper AH, Samuels MA, Klein J. Adams and Victor's Principles of Neurology. 11. McGraw-Hill Education; 2019. pp. 1336&#x2013;1339.</Citation></Reference><Reference><Citation>Krishnan AV, Kiernan MC. Altered nerve excitability properties in established diabetic neuropathy. Brain. 2005;128:1178&#x2013;1187. doi: 10.1093/brain/awh476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh476</ArticleId><ArticleId IdType="pubmed">15758031</ArticleId></ArticleIdList></Reference><Reference><Citation>Misawa S, Kuwabara S, Ogawara K, Kitano Y, Hattori T. Strength-duration properties and glycemic control in human diabetic motor nerves. Clin. Neurophysiol. 2005;116:254&#x2013;258. doi: 10.1016/j.clinph.2004.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2004.08.003</ArticleId><ArticleId IdType="pubmed">15661101</ArticleId></ArticleIdList></Reference><Reference><Citation>Akca G, Yerdelen D, Balci MK, Uysal H. The effects of hyperventilation on axonal excitability parameters in patients with diabetes mellitus and polyneuropathy. Diabetes Res. Clin. Pract. 2016;118:112&#x2013;120. doi: 10.1016/j.diabres.2016.04.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2016.04.058</ArticleId><ArticleId IdType="pubmed">27368063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gencpinar P, Celmeli G, Duman O, Haspolat S, Uysal H. Tibial nerve axonal excitability in type 1 diabetes mellitus. Muscle Nerve. 2019;59:76&#x2013;81. doi: 10.1002/mus.26303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26303</ArticleId><ArticleId IdType="pubmed">30019351</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson DL, Cox MM, Lehninger AL. Lehninger Principles of Biochemistry. 7. W.H. Freeman and Company; 2017. pp. 526&#x2013;527.</Citation></Reference><Reference><Citation>van Eijk RPA, et al. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry. 2018;89:156&#x2013;161. doi: 10.1136/jnnp-2017-317077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317077</ArticleId><ArticleId IdType="pmc">PMC5800333</ArticleId><ArticleId IdType="pubmed">29084868</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A, Moritz T, Marklund SL, Antti H, Andersen PM. Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS. PLoS ONE. 2011;6:e17947. doi: 10.1371/journal.pone.0017947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017947</ArticleId><ArticleId IdType="pmc">PMC3070699</ArticleId><ArticleId IdType="pubmed">21483737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph. Lateral Scler. Frontotemporal Degener. 2014;15:362&#x2013;370. doi: 10.3109/21678421.2014.908311.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.908311</ArticleId><ArticleId IdType="pubmed">24984169</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T, De Bock K, Van Den Bosch L. Energy metabolism in ALS: An underappreciated opportunity? Acta Neuropathol. 2018;135:489&#x2013;509. doi: 10.1007/s00401-018-1835-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1835-x</ArticleId><ArticleId IdType="pmc">PMC5978930</ArticleId><ArticleId IdType="pubmed">29549424</ArticleId></ArticleIdList></Reference><Reference><Citation>Shearer J, Weljie AM. In: Metabolomics and Systems Biology in Human Health and Medicine. Jones OAH, editor. CABI; 2014. pp. 157&#x2013;170.</Citation></Reference><Reference><Citation>Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve. 1998;21:137&#x2013;158. doi: 10.1002/(SICI)1097-4598(199802)21:2&lt;137::AID-MUS1&gt;3.0.CO;2-C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4598(199802)21:2&lt;137::AID-MUS1&gt;3.0.CO;2-C</ArticleId><ArticleId IdType="pubmed">9466589</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WQ, et al. Role of taurine in regulation of intracellular calcium level and neuroprotective function in cultured neurons. J. Neurosci. Res. 2001;66:612&#x2013;619. doi: 10.1002/jnr.10027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10027</ArticleId><ArticleId IdType="pubmed">11746381</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JY, Prentice H. Role of taurine in the central nervous system. J. Biomed. Sci. 2010;17:S1. doi: 10.1186/1423-0127-17-S1-S1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-17-S1-S1</ArticleId><ArticleId IdType="pmc">PMC2994408</ArticleId><ArticleId IdType="pubmed">20804583</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari N, Prentice H, Wu JY. Taurine and its neuroprotective role. Adv. Exp. Med. Biol. 2013;775:19&#x2013;27. doi: 10.1007/978-1-4614-6130-2_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4614-6130-2_2</ArticleId><ArticleId IdType="pubmed">23392921</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino Y, Koike H, Akai K. Free amino acids in motor cortex of amyotrophic lateral sclerosis. Experientia. 1979;35:219&#x2013;220. doi: 10.1007/BF01920627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01920627</ArticleId><ArticleId IdType="pubmed">421837</ArticleId></ArticleIdList></Reference><Reference><Citation>Malessa S, Leigh PN, Bertel O, Sluga E, Hornykiewicz O. Amyotrophic lateral sclerosis: Glutamate dehydrogenase and transmitter amino acids in the spinal cord. J. Neurol. Neurosurg. Psychiatry. 1991;54:984&#x2013;988. doi: 10.1136/jnnp.54.11.984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.54.11.984</ArticleId><ArticleId IdType="pmc">PMC1014621</ArticleId><ArticleId IdType="pubmed">1686899</ArticleId></ArticleIdList></Reference><Reference><Citation>Galarreta M, Bustamante J, Martin del Rio R, Solis JM. Taurine induces a long-lasting increase of synaptic efficacy and axon excitability in the hippocampus. J. Neurosci. 1996;16:92&#x2013;102. doi: 10.1523/JNEUROSCI.16-01-00092.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.16-01-00092.1996</ArticleId><ArticleId IdType="pmc">PMC6578712</ArticleId><ArticleId IdType="pubmed">8613813</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobrido-Camean D, et al. Taurine promotes axonal regeneration after a complete spinal cord injury in lampreys. J. Neurotrauma. 2020;37:899&#x2013;903. doi: 10.1089/neu.2019.6604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2019.6604</ArticleId><ArticleId IdType="pubmed">31469029</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogyoros I, Kiernan MC, Burke D, Bostock H. Strength-duration properties of sensory and motor axons in amyotrophic lateral sclerosis. Brain. 1998;121(Pt 5):851&#x2013;859. doi: 10.1093/brain/121.5.851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/121.5.851</ArticleId><ArticleId IdType="pubmed">9619189</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostock H, Sharief MK, Reid G, Murray NM. Axonal ion channel dysfunction in amyotrophic lateral sclerosis. Brain. 1995;118(Pt 1):217&#x2013;225. doi: 10.1093/brain/118.1.217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/118.1.217</ArticleId><ArticleId IdType="pubmed">7534598</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin. Neurophysiol. 2006;117:1458&#x2013;1466. doi: 10.1016/j.clinph.2006.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2006.04.016</ArticleId><ArticleId IdType="pubmed">16759905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusaczuk M. Tauroursodeoxycholate-bile acid with chaperoning activity: Molecular and cellular effects and therapeutic perspectives. Cells. 2019 doi: 10.3390/cells8121471.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8121471</ArticleId><ArticleId IdType="pmc">PMC6952947</ArticleId><ArticleId IdType="pubmed">31757001</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N. Engl. J. Med. 2020;383:919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaise BJ, et al. Power analysis and sample size determination in metabolic phenotyping. Anal. Chem. 2016;88:5179&#x2013;5188. doi: 10.1021/acs.analchem.6b00188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.6b00188</ArticleId><ArticleId IdType="pubmed">27116637</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SB, Kiernan MC, Vucic S. Axonal excitability in amyotrophic lateral sclerosis: Axonal excitability in ALS. Neurotherapeutics. 2017;14:78&#x2013;90. doi: 10.1007/s13311-016-0492-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0492-9</ArticleId><ArticleId IdType="pmc">PMC5233634</ArticleId><ArticleId IdType="pubmed">27878516</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, et al. Axonal ion channel dysfunction in c9orf72 familial amyotrophic lateral sclerosis. JAMA Neurol. 2015;72:49&#x2013;57. doi: 10.1001/jamaneurol.2014.2940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2940</ArticleId><ArticleId IdType="pubmed">25384182</ArticleId></ArticleIdList></Reference><Reference><Citation>Teruya T, Chen YJ, Kondoh H, Fukuji Y, Yanagida M. Whole-blood metabolomics of dementia patients reveal classes of disease-linked metabolites. Proc. Natl. Acad. Sci. U.S.A. 2021 doi: 10.1073/pnas.2022857118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2022857118</ArticleId><ArticleId IdType="pmc">PMC8449400</ArticleId><ArticleId IdType="pubmed">34493657</ArticleId></ArticleIdList></Reference><Reference><Citation>McGarrah RW, Crown SB, Zhang GF, Shah SH, Newgard CB. Cardiovascular metabolomics. Circ. Res. 2018;122:1238&#x2013;1258. doi: 10.1161/CIRCRESAHA.117.311002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.117.311002</ArticleId><ArticleId IdType="pmc">PMC6029726</ArticleId><ArticleId IdType="pubmed">29700070</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ZZ, Gerszten RE. Metabolomics and proteomics in type 2 diabetes. Circ. Res. 2020;126:1613&#x2013;1627. doi: 10.1161/CIRCRESAHA.120.315898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.315898</ArticleId><ArticleId IdType="pubmed">32437301</ArticleId></ArticleIdList></Reference><Reference><Citation>Au A. Metabolomics and lipidomics of ischemic stroke. Adv. Clin. Chem. 2018;85:31&#x2013;69. doi: 10.1016/bs.acc.2018.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.acc.2018.02.002</ArticleId><ArticleId IdType="pubmed">29655461</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohashi Y, et al. Depiction of metabolome changes in histidine-starved Escherichia coli by CE-TOFMS. Mol. Biosyst. 2008;4:135&#x2013;147. doi: 10.1039/b714176a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/b714176a</ArticleId><ArticleId IdType="pubmed">18213407</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooga T, et al. Metabolomic anatomy of an animal model revealing homeostatic imbalances in dyslipidaemia. Mol. Biosyst. 2011;7:1217&#x2013;1223. doi: 10.1039/c0mb00141d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c0mb00141d</ArticleId><ArticleId IdType="pubmed">21258713</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6:78&#x2013;95. doi: 10.1007/s11306-009-0178-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11306-009-0178-y</ArticleId><ArticleId IdType="pmc">PMC2818837</ArticleId><ArticleId IdType="pubmed">20300169</ArticleId></ArticleIdList></Reference><Reference><Citation>Junker BH, Klukas C, Schreiber F. VANTED: A system for advanced data analysis and visualization in the context of biological networks. BMC Bioinform. 2006;7:109. doi: 10.1186/1471-2105-7-109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-7-109</ArticleId><ArticleId IdType="pmc">PMC1413562</ArticleId><ArticleId IdType="pubmed">16519817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: A new approach in clinical testing. Muscle Nerve. 2000;23:399&#x2013;409. doi: 10.1002/(SICI)1097-4598(200003)23:3&lt;399::AID-MUS12&gt;3.0.CO;2-G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4598(200003)23:3&lt;399::AID-MUS12&gt;3.0.CO;2-G</ArticleId><ArticleId IdType="pubmed">10679717</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>